TITLE

Safety Profile of Bevantolol

AUTHOR(S)
Bray, John S.
PUB. DATE
March 1986
SOURCE
Angiology;Mar1986 Part 2, Vol. 37 Issue 3, p248
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Double-blind and long-term open-label studies have demonstrated a remarkably favorable safety profile for bevantolol. The drug was associated with a low incidence of adverse experiences similar to that observed with placebo. The adverse experiences were mostly mild to moderate and of the types found previously for other beta-blocking drugs. Very few patients withdrew from clinical studies because of adverse effects. Some patients continued on study for over four years. Bevantolol offers safe beta-blocking activity for the long-term treatment of angina and hypertension.
ACCESSION #
16365116

 

Related Articles

  • Re-examining the efficacy of β-blockers for the treatment of hypertension: a meta-analysis. Khan, Nadia; McAlister, Finlay A. // CMAJ: Canadian Medical Association Journal;6/6/2006, Vol. 174 Issue 12, p1737 

    Background: In a recently published meta-analysis, investigators asserted that β-blockers should not be used to treat hypertension. Because the pathophysiology of hypertension differs in older and younger patients, we designed this metaanalysis to clarify the efficacy of β-blockers in...

  • Pediatric blood pressure guidelines get an update.  // Drug Topics;6/7/2004, Vol. 148 Issue 11, p8 

    This article reports that the National High Blood Pressure Education Program Working Group has revised its guidelines regarding the treatment of hypertension in children and adolescents. This fourth report, which updates the group's 1996 guidelines, states that pharmacological therapy for...

  • JNC 7 one year later: Experts confirm, challenge its findings. Alexander, Walter // Drug Topics;7/26/2004, Vol. 148 Issue 14, p17 

    This article reports that recommendations of the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) were both supported and questioned in separate presentations at the American Society of Hypertension's 19th Annual...

  • Can we identify response markers to antihypertensive drugs? First results from the IDEAL Trial. Gueyffier, F; Subtil, F; Bejan-Angoulvant, T; Zerbib, Y; Baguet, J P; Boivin, J M; Mercier, A; Leftheriotis, G; Gagnol, J P; Fauvel, J P; Giraud, C; Bricca, G; Maucort-Boulch, D; Erpeldinger, S // Journal of Human Hypertension;Jan2015, Vol. 29 Issue 1, p22 

    Current antihypertensive strategies do not take into account that individual characteristics may influence the magnitude of blood pressure (BP) reduction. Guidelines promote trial-and-error approaches with many different drugs. We conducted the Identification of the Determinants of the Efficacy...

  • NICE signals significant changes in BP guidance.  // Pulse;11/5/2005, Vol. 65 Issue 43, p4 

    Reports on the study which found that the ASCOT trial is likely to have a significant impact on new NICE and British Hypertension Society guidelines for hypertension in Great Britain. Confirmation of the need for a wider evaluation of hypertension guidance; Improvement of the first-line therapy;...

  • Advantages and Disadvantages of Beta- Adrenergic Blocking Drugs in Hypertension. O'Brien, Eoin T. // Angiology;Apr1978, Vol. 29 Issue 4, p332 

    This paper reviews the role of beta-adrenergic blocking drugs in the treatment of hypertension. A significant proportion of patients presenting with mild or moderate hypertension will respond to general measures and do not require specific drug therapy. Of the remaining patients, some will...

  • Cellular Therapy With Ixmyelocel-T to Treat Critical Limb Ischemia: The Randomized, Double-blind, Placebo-controlled RESTORE-CLI Trial. Powell, Richard J; Marston, William A; Berceli, Scott A; Guzman, Raul; Henry, Timothy D; Longcore, Amy T; Stern, Theresa P; Watling, Sharon; Bartel, Ronnda L // Molecular Therapy;Jun2012, Vol. 20 Issue 6, p1280 

    Ixmyelocel-T is a patient-specific, expanded, multicellular therapy evaluated in patients with lower extremity critical limb ischemia (CLI) with no options for revascularization. This randomized, double-blind, placebo-controlled, phase 2 trial (RESTORE-CLI) compared the efficacy and safety of...

  • Effects of Buflomedil on Erythrocyte Deformability. Dormandy, J. A.; Ernst, E. // Angiology;Oct1981, Vol. 32 Issue 10, p714 

    This brief communication outlines recent experiments on the effects of buflomedil, a new vasoactive agent, on red cell deformability in patients with leg ischemia. In this randomized, double-blind cross-over study, 10 patients received 200 mg buflomedil and matching placebo intravenously. Red...

  • SUGAR PILLS: Docs' New Favorite Medicine?  // Prevention;May2008, Vol. 60 Issue 5, p32 

    The article presents statistics regarding the percentage of doctors who have prescribed placebos to patients and their reasons for doing so.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics